A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT Atherosclerosis Study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 109, Issue 9, 2002, Pages 1056-1062

  Clarke, S C ^a   Kelleher, J ^a   Lloyd Jones, H ^a   Slack, M ^b   Schofield, P M ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b HINCHINGBROOKE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADMINISTRATION, CUTANEOUS; AGED; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; DEATH, SUDDEN, CARDIAC; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HOSPITALIZATION; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036754747     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2002.01544.x     Document Type: Article

References (44)

1. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-63.
2. Grady D., Rubin S.M., Petitti DBet al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med. 117:1992;1016-1037.
3. Psaty B.M., Heckbert S.R., Atkins Det al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 154:1994;1333-1339.
4. Sidney S., Petitti D.B., Quesenberry C.P. Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 127:1997;501-508.
5. Petitti D.B., Perlman J.A., Sidney S. Postmenopausal oestrogen use and ischaemic heart disease. N Engl J Med. 315:1986;131-132.
6. Stampfer M.J., Colditz G.A., Willett WCet al. Post menopausal oestrogen therapy and cardiovascular disease: ten year follow up from the Nurses' Health Study. N Engl J Med. 325:1991;756-762.
7. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 115:1991;455-456.
8. Petitti D.B. Coronary heart disease and estrogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol. 4:1994;115-118.
9. Wilkinson P., Laji K., Ranjadayalan K., Parsons L., Timmis A. Acute myocardial infarction in women: survival analysis in the first six months. BMJ. 309:1994;566-569.
10. Bush T.L., Barrett-Connor E., Cowan LDet al. Cardiovascular mortality and non contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 75:1987;1102-1109.
11. Sullivan J.M., Vander Zwaag R., Hughes JPet al. Estrogen replacement and coronary artery disease. Arch Intern Med. 150:1990;2557-2562.
12. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 151:1991;75-78.
13. O'Brien J.E., Peterson E.D., Keeler GPet al. Relation between estrogen replacement therapy and restenosis after percutaneous interventions. J Am Coll Cardiol. 28:1996;1111-1118.
14. Newton K.M., La Croix A.Z., McKnight Bet al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol. 145:1997;269-277.
15. Sullivan J.M., El-Zeky F., Vander Zwaag R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol. 79:1997;847-850.
16. Hulley S., Grady D., Bush Tet al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
17. Stephens N., Parsons A., Schofield PMet al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
18. WHO Scientific Group Research on the menopause WHO technical report series. Geneva 1981;670:53-68.
19. Gambrell R.D. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril. 7:1981;457-474.
20. Whitehead M.I., Padwick M., Endacott J., Pryse-Davies J. Endometrial responses to transdermal oestradiol in post menopausal women. Am J Obstet Gynecol. 152(8):1985;1079-1084.
21. Campbell S., McQueen J., Minardi J., Whitehead M.I. The modifying effects of progestogen on the response of the post menopausal endometrium to exogenous oestrogens. Postgrad Med J. 54(Suppl 2):1978;59-64.
22. Gambrell R.D. Sex steroids and cancer. Obstet Gynecol Clin North Am. 14:1987;191-206.
23. Palomaki P., Miettinen H., Mustaniemi Het al. Diagnosis of acute myocardial infarction by MONICA and FINMONICA diagnostic criteria in comparison with hospital discharge diagnosis. J Clin Epidemiol. 47:1994;659-666.
24. Braunwald E., Jones R.H., Mark DBet al. Diagnosing and managing unstable angina: agency for health care policy and research. Circulation. 90:1994;613-622.
25. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than non-users? Am J Epidemiol. 143:1996;971-978.
26. Grodstein F., Stampfer M.J., Manson JEet al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
27. Falkeborn M., Persson I., Adami Het al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 99:1992;821-828.
28. Mann R.D., Lis Y., Chukwujindu J., Chanter D.O. A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. J Clin Epidemiol. 47:1994;307-312.
29. Samaan S.A., Crawford M.H. Estrogen and cardiovascular function after menopause. J Am Coll Cardiol. 26:1995;1403-1410.
30. Guetta V., Cannon R.O. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation. 93:1996;1928-1937.
31. Bush D.E., Jones C.E., Bass KMet al. Estrogen therapy reverses endothelial dysfunction in post menopausal women. Am J Med. 104(b):1998;552-558.
32. Gerhard M., Walsh B.W., Tawakol Aet al. Estradoil therapy combined with progesterone and endothelium dependent vasodilatation in post menopausal women. Circulation. 98(12):1998;1158-1163.
33. Sarrel P.M. How progestins compromise the cardioprotective effects of estrogens. Menopause. 2:1995;187-190.
34. Writing Group for the PEPI trial Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA. 273:1995;199-208.
35. Clarke S.C., Kirschenlohr H.L., Metcalfe J.C., Schofield P.M. Hormone replacement therapy enhances endothelium dependent vasodilatation in postmenopausal women with angiographically proven coronary atherosclerosis. Heart. 83(5):2000;70. [abstract].
36. Kardos A., Casadei B. Hormone replacement therapy and ischaemic heart disease among post menopausal women. J Cardiovasc Risk. 6:1999;105-112.
37. Frick M.H., Elo O., Haapa Ket al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med. 317:1987;1237-1245.
38. Shepherd J., Cobbe S.M., Ford Iet al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 33:1995;1301-1307.
39. Sacks F.M., Pfeffer M.A., Moye LAet al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
40. Jick H., Derby L.E., Meyers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
41. Grodstein F., Stampfer M.J., Goldhaber SZet al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
42. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
43. Gutthann S.P., Rodriguez L.A.G., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 314:1997;796-800.
44. Collaborative group on hormonal factors in breast cancer Lancet. 350:1997;1047-1059.